and 18 hospitalized patients) with CMV infection were identified. The most frequent symptoms were malaise (67%), fever (46%), and sweats (46%), and the most frequent finding was abnormal liver function test results (69%). Twelve percent of patients had a relapsing illness, and many had symptoms that lasted for up to 32 weeks (mean duration of symptoms, 7.8 weeks). GPs reported that there was a significant benefit in making the diagnosis of CMV infection; it provided reassurance and avoided the need for further investigations. We have identified symptoms associated with CMV infection in immunocompetent patients who present to GPs or who are admitted to the hospital.
relapsing illness involving fever, sweats, and malaise in grandmothers who acquired infection from their grandchildren [19] . Following up this work, we conducted a study in which we sought evidence of CMV infection in immunocompetent patients in the community and in hospitals in Cambridge and Chelmsford, United Kingdom, during 1998-2001. We describe the symptoms, report the duration of symptoms, and demonstrate the value of diagnosis of CMV infection in immunocompetent patients.
METHODS

Patients.
Immunocompetent patients with evidence of recent CMV infection (CMV IgM level, 1300 U/mL) were selected for the study. Patients with hematological and/or oncological disorders, those who had received transplants, and those receiving immunosuppressive therapy (excluding low-dose steroid therapy) were excluded from the study. The study group comprised 124 (1.63%) of 7630 patients whose serum samples were tested during the period of December 1998 through June 2001 in the Cambridge and Chelmsford Public Health Laboratories. Patients' serum samples were selected for CMV IgM testing if they presented with pyrexia, malaise, lymphadenopathy, jaundice, hepatitis, sweats, or a glandular fever-like illness.
CMV IgM detection. CMV infection was diagnosed by the detection of CMV-specific IgM in serum samples (Eurogenetics CMV IgM ELISA assay). Patients were only included in the study if they had CMV-specific IgM levels of 1300 U/mL in the absence of Epstein-Barr virus, hepatitis A, antibody to hepatitis B core antigen, and Toxoplasma gondii IgM antibodies and of rheumatoid factor.
CMV IgG avidity. The specificity of our CMV IgM assay was verified by performing CMV IgG avidity tests on all available samples from the study by using a modified CMV IgG EIA (Biokit) and 8M urea.
Clinical data. Four to 12 months after CMV infection was diagnosed, a questionnaire was sent to the patient's general practitioner (GP) to document the symptoms, duration of symptoms, and clinical value of diagnosis. GPs were also asked whether the patient had been receiving immunosuppressive drugs or had a malignant disease. If the questionnaires were not returned, GPs were telephoned for the information. Medical records of hospitalized patients were scrutinized to gain similar information.
RESULTS
During the study period (December 1998 through June 2001), 124 patients (106 of whom presented to their GPs and 18 of whom were hospitalized) with CMV infection (CMV IgM level, 1300 U/mL) were detected. The ratio of male to female patients was 1.2:1. The age range was 16-86 years (table 1) . CMV IgG avidity was used to confirm acute CMV infection.
In patients for whom a recent date of symptom onset (!2 weeks) was known, CMV IgM was always detectable. However, in most of these patients, CMV IgG was not detected at the time of study (i.e., !2 weeks after symptom onset). Additional serum samples were sought from these patients, and CMV IgG appeared 2-3 weeks after the onset of symptoms. In patients for whom serial serum samples were available, IgM was detectable for 4-6 months after the onset of symptoms.
The age distribution of patients with CMV infection is shown in figure 1 . Infection was most frequently found in patients aged 20-59 years (90% of all patients). The most typical clusters of symptoms associated with CMV infection in these immunocompetent patients are shown in table 1 and include abnormal liver function test (LFT) findings, malaise, jaundice, sweats, and pyrexia. In total, 32% of patients had this combination of symptoms.
Patients for whom LFTs were performed had the following laboratory values: mean alanine aminotransferase level, 121 U/ L (range, 23-1151 U/L); mean alkaline phosphatase level, 162 U/L (range, 44-1342 U/L); and mean bilirubin level, 22 mmol/ L (range, 6-349 mmol/L). Among patients for whom the temperature was measured, the mean temperature was 38.3ЊC (range, 37.2ЊC-40.0ЊC). Among those patients who had sweats, 60% had at sweats at night, 24% had them during the day, and 16% had them during both day and night. Among those patients who had lymphadenopathy, 88% and 16% had cervical and inguinal glands, respectively. Symptoms in community and hospitalized patients were broadly similar (table 1) . However, hospitalized patients had a higher incidence of abnormal LFT findings, malaise, sweats, pyrexia, respiratory symptoms, confusion, and abdominal pain but a lower incidence of lymphadenopathy.
Fifteen patients (12%) had a relapsing illness (with clinical improvement followed by recurrent symptoms) (table 1). The duration of symptoms was 1-32 weeks (mean duration, 7.8 weeks). The initial diagnoses made by GPs for 68 of these patients are shown in table 2.
The response rate of GPs to questionnaires was 82%. All GPs were asked whether their patients with CMV infection had a malignancy or were receiving immunosuppressive drugs around the time of diagnosis of CMV infection. Eighty-seven of 91 patients for whom information was received had not been given immunosuppressive drugs, nor was a malignant disease diagnosed within 4-12 months of the CMV infection. The other 4 patients had received steroid treatment 2-4 months before the onset of CMV infection.
Four patients were pregnant at the time of CMV infection. Three delivered apparently healthy children, but 1 child had interuterine growth retardation and was born with severe hearing impairment.
There was significant benefit in making a diagnosis of CMV infection in these patients. For 35 patients (33%) seen by GPs, there was relief that the prolonged illness was not serious and would eventually resolve with no sequelae. For 6 patients (6%) seen by GPs, diagnosis of CMV infection avoided further investigations. Two patients were scheduled to have liver biopsies when CMV infection was diagnosed.
DISCUSSION
Severe CMV disease is usually associated with infection in immunocompromised patients [4] [5] [6] [7] [8] [9] . There are few reports of severe or prolonged symptomatic infection in immunocompetent patients [10] [11] [12] [13] [14] [15] [16] [17] [18] . Most of these studies have reported hepatitis [10, 11, 14] and colitis [16] [17] [18] in association with CMV infection. In the largest study, Faucher et al. [14] performed a retrospective analysis of 116 hospitalized patients and outpatients. Fever was noted in 99% of patients, with a mean duration of 21 days. Fifty-one percent of patients had headache, 46% had myalgia, and 36% had splenomegaly. Respiratory and neurological symptoms were noted in 8% and 1% of patients, respectively.
In 1995, we reported a study of older patients who had acquired CMV infection from their congenitally infected newborn grandchildren and who had malaise [19] . We described this as the "feverish granny syndrome," and that study heightened our interest in the diagnosis of CMV infection in immunocompetent patients. In 1998, we reviewed the criteria that we used for selecting serum samples to be tested for CMV IgM and expanded the range of symptoms to include malaise, fever, hepatitis, elevated LFT values, lymphadenopathy, glandular fever-like illness, sore throat, and sweats. In the subsequent 3 months, we observed an increase in the number of patients with CMV infection who had presented to their GPs. We had issued an interim analysis of the results in our Cambridge GP newsletter, presented our findings at 3 GP meetings, and asked them to take part in our study of CMV infection in immunocompetent patients. Several GPs began referring samples in which they suspected-with a good degree of accuracy-CMV infection. We also extended our study to GPs referring samples to Chelmsford Public Health Laboratory and sought evidence of CMV infection in hospitalized immunocompetent patients in Cambridge and Chelmsford.
CMV infection was diagnosed by detecting CMV-specific IgM in the absence of other diagnoses of viral and T. gondii infections. This test can have nonspecific results associated with lower CMV IgM levels. Therefore, we only considered patients with CMV IgM levels of 1300 U/mL as having evidence of recent CMV infection. Most patients had much higher amounts of CMV IgM (up to 1000 U/mL). Serum samples obtained from these patients were also positive for low-avidity CMV IgG. Although no reference standard test for the diagnosis of primary CMV infection exists, determination of CMV IgG avidity has been used in several studies to distinguish accurately between recent and past CMV infection [20] [21] [22] .
Eighty-five percent of the patients in our study with symptomatic CMV infection presented to their GPs, and 15% of patients were hospitalized inpatients. It cannot be assumed that 15% of all immunocompetent patients with CMV infection will be hospitalized, because many patients with milder illness will not present to their GPs or have samples sent to the laboratory. As can be seen in table 1, hospitalized patients had more-severe symptoms. Patients who presented to GPs were an unselected group that represented the local community. Many patients had prolonged and/or relapsing symptoms, and few GPs had suspected CMV infection in their initial diagnosis until later in the study period, when they had become more familiar with the typical presenting symptoms (i.e., pyrexia, malaise, and hepatitis/abnormal LFT findings).
Antiviral drugs, such as ganciclovir, are available for treating CMV infection, but they are licensed for use only in severe or life-threatening illness in immunocompromised patients. Despite the nonavailability of antiviral treatment for immunocompetent patients, GPs reported that diagnosing CMV infection had benefits. In particular, although symptoms may be prolonged (up to 32 weeks; table 1), all patients could be reassured that symptoms would eventually resolve and that there would be no sequelae. They also gained reassurance that additional investigations were not required.
None of our patients with CMV infection had malignancies; however, because symptomatic CMV infection can be more prevalent among these patients, malignancies must always be considered a possibility. Four of our patients were receiving steroid treatment (prednisolone, 3-20 mg q.d., for 2-4 months before onset of symptoms), which increases the incidence of symptomatic CMV infection. We believe that, by recognizing the range of symptoms associated with CMV infection in immunocompetent patients and by diagnosing infection more frequently, there is significant benefit for patients and doctors.
